Post-comatose disorders of consciousness (DoC) represent persistent neurological conditions with limited therapeutic options and a poor prognosis. Recent works advocate for exploring the effects of psychedelics to enhance brain complexity in DoC and ameliorate their consciousness. We investigated sub-anesthetic concentration of the atypical psychedelic ketamine for treating post-comatose prolonged DoC through a double-blind, placebo-controlled, cross-over trial involving three adult patients. Incremental concentrations of intravenous ketamine and saline were administered, alongside continuous electroencephalogram (EEG) recording and assessments of conscious behaviors and spastic paresis. Brain complexity, measured by Lempel-Ziv complexity (LZC) and explainable consciousness indicator (ECI), revealed increased LZC during ketamine infusion but no change in ECI. Patients exhibited reduced spastic paresis and increased arousal as time spent with eyes open but no positive change in diagnosis. No adverse effects were noted. This study contributes to understanding the relationship between consciousness and brain complexity and suggests a potential therapeutic role for ketamine in DoC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780106 | PMC |
| http://dx.doi.org/10.1016/j.isci.2024.111639 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
α-Phellandrene: A Promising Natural Remedy for Rotenone-Induced Parkinson's Disease.
Recent Adv Food Nutr Agric
January 2025
Rajiv Academy for Pharmacy, Mathura, U.P. India.
Parkinson's Disease (PD) is a neurodegenerative disorder characterized by the pro-gressive loss of dopaminergic neurons in the substantia nigra, leading to motor dysfunction and non-motor symptoms. Current treatments primarily offer symptomatic relief without halt-ing disease progression. This has driven the exploration of natural compounds with neuropro-tective properties.
View Article and Find Full Text PDFChallenges for switching central nervous system and psychiatric medication products: A review of the literature.
J Psychopharmacol
January 2025
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Background: Switching between versions of medication products happens commonly despite challenges in achieving bioequivalence and therapeutic equivalence. Central nervous system and psychiatric drugs, especially those that are technically demanding to manufacture and have complex pharmacokinetic properties, such as long-acting injectables (LAIs), pose particular challenges to bioequivalence and safe and efficacious drug switching.
Aims: To assess whether drugs deemed "bioequivalent" are truly interchangeable in drug switching.
AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships.
Comput Struct Biotechnol J
January 2025
Ph.D. Program in Computer Science, The Graduate Center, The City University of New York, New York, NY, USA.
Despite the wealth of single-cell multi-omics data, it remains challenging to predict the consequences of novel genetic and chemical perturbations in the human body. It requires knowledge of molecular interactions at all biological levels, encompassing disease models and humans. Current machine learning methods primarily establish statistical correlations between genotypes and phenotypes but struggle to identify physiologically significant causal factors, limiting their predictive power.
View Article and Find Full Text PDFA pilot human study using ketamine to treat disorders of consciousness.
iScience
January 2025
Coma Science Group, GIGA-Consciousness, University of Liège, Liège, Belgium.
Post-comatose disorders of consciousness (DoC) represent persistent neurological conditions with limited therapeutic options and a poor prognosis. Recent works advocate for exploring the effects of psychedelics to enhance brain complexity in DoC and ameliorate their consciousness. We investigated sub-anesthetic concentration of the atypical psychedelic ketamine for treating post-comatose prolonged DoC through a double-blind, placebo-controlled, cross-over trial involving three adult patients.
View Article and Find Full Text PDFNovel youth mental health services in Australia: What differences are being reported about the clinical needs of those who attend and the outcomes achieved?
Aust N Z J Psychiatry
February 2025
Brain and Mind Centre, The University of Sydney, Camperdown, NSW, Australia.
Globally, youth mental health services are evolving, with Australia's services presented as a leading exemplar. services were designed as enhanced primary care-based entities and were expected to collaborate with local acute, and specialist clinical and psychosocial services. The lack of large-scale health services trials necessitates understanding their impact through systematic monitoring and evaluation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!